Navigation Links
DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
Date:1/25/2013

s and the potential to generate near-term revenue through product sales or royalties for the approved indications in China while seeking global approval in new indications.

DelMar will continue the business of DelMar Pharmaceuticals (BC) Ltd., headquartered in Vancouver, British Columbia with clinical operations in Menlo Park, CA, as a subsidiary under the leadership of DelMar Pharmaceuticals (BC) Ltd.'s current management team, headed by Chief Executive Officer Jeffrey Bacha . In connection with the Acquisition, DelMar issued to the former shareholders of DelMar Pharmaceuticals (BC) Ltd. the equivalent of 13,070,000 shares of its common stock.  Details of the transaction will be filed on a Form 8-K with the United States Securities and Exchange Commission.

The securities sold in the private placement have not been registered under the Securities Act of 1933 and may not be resold absent registration under or exemption from such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act of 1933.

About DelMar Pharma
Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... It is now possible to separate two ... photon emission computed tomography (SPECT) according to researchers from Amen Clinics, UCLA, Thomas ... brain scans and is believed to be the largest brain imaging study ever, will ...
(Date:7/1/2015)... , July 1, 2015   Decision Resources ... cited advantages of Otezla are its oral administration, ... as reported by surveyed rheumatologists. Otezla was the ... the treatment of active psoriatic arthritis in ... standard of care includes conventional oral treatments including ...
(Date:7/1/2015)... Colo. and BANGALORE, India ... global genomic profiling company that uses next generation sequencing ... of Scott A. Storrer as chief executive ... CEO, he will be responsible for all strategy, business ... Chandru , who has served as Strand,s chairman and ...
(Date:7/1/2015)... HAMILTON, Bermuda , July 1, 2015 /PRNewswire/ ... biopharmaceutical company focused on the treatment of dementia, ... investor briefing on July 22 at 5:45 p.m. ... at the Alzheimer,s Association International Conference 2015 (AAIC). ... following remarks: , Dr. Lawrence ...
Breaking Biology Technology:Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3
... identified, search engines are leading the way for consumers ... related to the efficacy of these search engines, among ... soon and why could this happen? , ,If search ... todays search results, which often include a great deal ...
... mentioned my first law of softwareany mildly successful software program ... operating system. Youve seen it. The e-mail system that gets ... in version three and so on. The ERP system that ... for this kind of behavior is the browser. , ,So ...
... campaign season, and you've been poked and prodded by television ... John Kerry drank a beer at your neighborhood bar and ... Dick Cheney was spotted more in Wisconsin in 2004 than ... years. John Edwards has been in the state so often ...
Cached Biology Technology:When search engines collide 2When search engines collide 3When search engines collide 4The first law of software 2The first law of software 3Twenty ways you can tell this campaign has finally pushed you over the edge 2
(Date:6/24/2015)... YORK , June 24, 2015 This ... market, over the next six years. It contains an ... the industry, along with their impact from the short, ... It also discusses the industry, market, and technology trends ... that the need of concerned authorities to efficiently manage ...
(Date:6/23/2015)... DUBLIN , June 22, 2015 ... has announced the addition of the "Body-Worn ... Share, Growth, Trends and Forecast 2014 - 2020" ... report offers strategic analysis of the global body-worn ... market has been segmented on the basis of ...
(Date:6/17/2015)... GERMANTOWN, Maryland , June 17, 2015 /PRNewswire/ ...   Produktlinie mit DNA-Tests verbessert den Analyseprozess und senkt ... ; Frankfurt Prime Standard: QIA) hat heute in den ... Investigator ® für die ... neuen Kits zur Erstellung genetischer Fingerabdrücke bieten eine integrierte ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6
... such as schizophrenia, major depression and cancer are ... dysfunctional genes. A novel computational biology method developed ... PhD, http://www.njit.edu/news/2008/2008-367.php , associate professor in NJIT,s ... a way to uncover the critical genes responsible ...
... WEST LAFAYETTE, Ind. Although research has linked inbreeding ... of animals, a new study finds it plays no ... Purdue University researchers recently examined 2,000 adult and ... deformities, mainly consisting of missing, extra or dwarfed digits ...
... NEW YORK, NY (October 28, 2008) The first ... exploring the role of hospital touch surfaces in the ... researchers reported their findings in a poster session at ... in Washington, D.C. on Tuesday, October 28. The ...
Cached Biology News:NJIT professor finds engineering technique to identify disease-causing genes 2Study rules out inbreeding as cause of amphibian deformities 2
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
...
... Antigen peptide transporter 2 ... (Peptide transporter PSF2) (Peptide ... (Peptide transporter involved in ... Antigen: ...
... Recognizes Nabeta2. The epitope specific ... in any other known proteins.,SPECIES ... to work on human because ... conserved (17/19 residues). Reactivity with ...
Biology Products: